Novo Nordisk Navigates Pipeline Promise and Payer Pushback

Novo Nordisk shares, trading near 33 euros, reflect a market grappling with the pharmaceutical giant’s dual narrative. While the company notches a significant clinical victory in sickle cell disease, its core weight-loss business faces mounting commercial headwinds in the crucial US market.

The Danish firm announced that its drug etavopivat met all primary endpoints in the pivotal HIBISCUS Phase 3 trial. The once-daily tablet for sickle cell disease demonstrated a 27% reduction in vaso-occlusive crises and improved blood parameters compared to a placebo. Novo Nordisk, which acquired the therapy through its $1 billion purchase of Forma Therapeutics in 2022, plans to file for regulatory approval in the second half of 2026. The drug already holds fast-track designation in the United States.

This pipeline success arrives as the company’s growth engine shows signs of strain. A major setback comes from the uncertain future of the US Medicare “BALANCE” program, designed to expand coverage for anti-obesity medications like Novo’s Wegovy. The April 20 deadline for insurer participation passed with a formal rejection from CVS Health and expressed concerns from UnitedHealth. For the program to launch as planned in early 2027, it requires backing from insurers representing a large portion of Medicare members.

Competitive and pricing pressures are intensifying. Rival Eli Lilly is aggressively challenging Novo’s dominance with new oral therapies, shifting market preference away from injectables. Concurrently, Novo Nordisk has announced plans to cut US list prices for its key semaglutide brands starting in early 2027, fueling investor anxiety over future profitability. The stock has lost over 25% since the start of the year, a decline that has halved its value from a 52-week high above 70 euros. A Relative Strength Index (RSI) reading of 24.6 indicates the shares are deeply oversold.

Should investors sell immediately? Or is it worth buying Novo Nordisk?

Management’s subdued outlook compounds these challenges. For 2026, the company forecasts a currency-adjusted decline in both sales and operating profit of 5% to 13%. This guidance cites factors including lower Medicaid reimbursements and the loss of exclusivity for semaglutid in some markets.

Amid this turbulence, Novo Nordisk is deploying capital to support its valuation and investing in long-term efficiency. A share buyback program totaling 15 billion Danish kroner, launched in February, is underway, with over 3 billion kroner repurchased by mid-April. In total, the company plans to return more than 60 billion kroner to shareholders this year. Operationally, a strategic partnership with OpenAI, announced in mid-April, aims to integrate artificial intelligence across all business areas to accelerate research and development.

The coming months demand clarity on US reimbursement structures for its blockbuster drugs. Until then, the promising data for etavopivat serves as a reminder of the company’s broader research ambitions beyond the fiercely contested GLP-1 market.